» Articles » PMID: 26338675

Shank Synaptic Scaffold Proteins: Keys to Understanding the Pathogenesis of Autism and Other Synaptic Disorders

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2015 Sep 5
PMID 26338675
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Shank/ProSAP proteins are essential to synaptic formation, development, and function. Mutations in the family of SHANK genes are strongly associated with autism spectrum disorders (ASD) and other neurodevelopmental and neuropsychiatric disorders, such as intellectual disability (ID), and schizophrenia. Thus, the term 'Shankopathies' identifies a number of neuronal diseases caused by alteration of Shank protein expression leading to abnormal synaptic development. With this review we want to summarize the major genetic, molecular, behavior and electrophysiological studies that provide new clues into the function of Shanks and pave the way for the discovery of new therapeutic drugs targeted to treat patients with SHANK mutations and also patients affected by other neurodevelopmental and neuropsychiatric disorders. Shank/ProSAP proteins are essential to synaptic formation, development, and function. Mutations in the family of SHANK genes are strongly associated with autism spectrum disorders (ASD) and other neurodevelopmental and neuropsychiatric disorders, such as intellectual disability (ID), and schizophrenia (SCZ). With this review we want to summarize the major genetic, molecular, behavior and electrophysiological studies that provide new clues into the function of Shanks and pave the way for the discovery of new therapeutic drugs targeted to treat patients with SHANK mutations.

Citing Articles

Shank3 modulates Rpl3 expression and protein synthesis via mGlu5: implications for Phelan McDermid syndrome.

Giona F, Beretta S, Zippo A, Stefanoni A, Tomasoni Z, Vicidomini C Mol Psychiatry. 2025; .

PMID: 40089604 DOI: 10.1038/s41380-025-02947-9.


Regulation of Dendrite and Dendritic Spine Formation by TCF20.

Vinci E, Beretta S, Colombo V, Zippo A, Catanese A, Wiegreffe C J Neurochem. 2025; 169(1):e16297.

PMID: 39801227 PMC: 11725998. DOI: 10.1111/jnc.16297.


Rodent Models for ASD Biomarker Development.

Lee H, Sahin M Adv Neurobiol. 2024; 40:189-218.

PMID: 39562446 DOI: 10.1007/978-3-031-69491-2_8.


Assessing the Neurodevelopmental Impact of Fluoxetine, Citalopram, and Paroxetine on Neural Stem Cell-Derived Neurons.

Hosseini K, Cediel-Ulloa A, Al-Sabri M, Forsby A, Fredriksson R Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459031 PMC: 11510426. DOI: 10.3390/ph17101392.


Decreased free D-aspartate levels in the blood serum of patients with schizophrenia.

Garofalo M, De Simone G, Motta Z, Nuzzo T, De Grandis E, Bruno C Front Psychiatry. 2024; 15:1408175.

PMID: 39050919 PMC: 11266155. DOI: 10.3389/fpsyt.2024.1408175.